Christopher A. Kuebler Sells 30,000 Shares of Nektar Therapeutics (NKTR) Stock

Nektar Therapeutics (NASDAQ:NKTR) Director Christopher A. Kuebler sold 30,000 shares of the company’s stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $58.66, for a total transaction of $1,759,800.00. Following the completion of the sale, the director now directly owns 70,500 shares in the company, valued at $4,135,530. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

Nektar Therapeutics (NKTR) traded up $0.48 during mid-day trading on Thursday, reaching $58.34. 1,420,563 shares of the company’s stock traded hands, compared to its average volume of 1,647,133. The company has a current ratio of 4.14, a quick ratio of 3.99 and a debt-to-equity ratio of 2.91. Nektar Therapeutics has a 12-month low of $11.41 and a 12-month high of $61.88. The company has a market capitalization of $9,190.00, a price-to-earnings ratio of -82.17 and a beta of 1.81.

Nektar Therapeutics (NASDAQ:NKTR) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share for the quarter, beating the consensus estimate of $0.21 by $0.16. Nektar Therapeutics had a negative net margin of 42.08% and a negative return on equity of 190.68%. The firm had revenue of $152.90 million during the quarter, compared to analyst estimates of $126.50 million. During the same quarter in the previous year, the firm earned ($0.32) earnings per share. The firm’s revenue for the quarter was up 321.2% compared to the same quarter last year. equities research analysts predict that Nektar Therapeutics will post -0.75 earnings per share for the current fiscal year.

NKTR has been the topic of several recent analyst reports. Roth Capital set a $45.00 price target on shares of Nektar Therapeutics and gave the company a “buy” rating in a report on Monday, November 13th. Canaccord Genuity Group boosted their target price on shares of Nektar Therapeutics from $35.00 to $50.00 and gave the company a “buy” rating in a research note on Wednesday, November 15th. Mizuho boosted their target price on shares of Nektar Therapeutics from $30.00 to $45.00 and gave the company a “buy” rating in a research note on Tuesday, November 14th. Cowen started coverage on shares of Nektar Therapeutics in a research note on Tuesday, November 7th. They set an “outperform” rating for the company. Finally, JPMorgan Chase & Co. reiterated a “buy” rating and set a $44.00 target price on shares of Nektar Therapeutics in a research note on Monday, November 13th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Nektar Therapeutics has an average rating of “Buy” and a consensus price target of $35.58.

Institutional investors have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its position in shares of Nektar Therapeutics by 0.6% during the second quarter. Bank of New York Mellon Corp now owns 2,138,632 shares of the biopharmaceutical company’s stock worth $41,812,000 after acquiring an additional 12,730 shares during the last quarter. Tocqueville Asset Management L.P. grew its position in shares of Nektar Therapeutics by 8.5% during the third quarter. Tocqueville Asset Management L.P. now owns 252,202 shares of the biopharmaceutical company’s stock worth $6,053,000 after acquiring an additional 19,800 shares during the last quarter. Ameriprise Financial Inc. grew its position in shares of Nektar Therapeutics by 9.1% during the second quarter. Ameriprise Financial Inc. now owns 952,443 shares of the biopharmaceutical company’s stock worth $18,620,000 after acquiring an additional 79,510 shares during the last quarter. Piedmont Investment Advisors LLC grew its position in shares of Nektar Therapeutics by 264.6% during the second quarter. Piedmont Investment Advisors LLC now owns 33,545 shares of the biopharmaceutical company’s stock worth $656,000 after acquiring an additional 24,344 shares during the last quarter. Finally, Systematic Financial Management LP grew its position in shares of Nektar Therapeutics by 1.8% during the third quarter. Systematic Financial Management LP now owns 745,979 shares of the biopharmaceutical company’s stock worth $17,903,000 after acquiring an additional 12,949 shares during the last quarter. Institutional investors and hedge funds own 96.01% of the company’s stock.

WARNING: This report was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another domain, it was illegally copied and republished in violation of United States & international trademark and copyright law. The original version of this report can be viewed at https://www.chaffeybreeze.com/2018/01/04/christopher-a-kuebler-sells-30000-shares-of-nektar-therapeutics-nktr-stock.html.

About Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply